Premium
Whole‐Body Composition in Patients With Angina Pectoris Receiving Long‐Term Treatment With the Nonselective Beta‐Receptor Blocking Drug Nadolol
Author(s) -
Gray J. M. B.,
East B. W.,
Robertson I.,
Preston T.,
Lawson D. H.
Publication year - 1986
Publication title -
the journal of clinical pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.92
H-Index - 116
eISSN - 1552-4604
pISSN - 0091-2700
DOI - 10.1002/j.1552-4604.1986.tb02957.x
Subject(s) - nadolol , angina , medicine , renal function , cardiology , anesthesia , propranolol , myocardial infarction
Nadolol is a nonselective beta‐adrenergic receptor antagonist used on a long‐term basis for therapy of angina and hypertension. It has been reported to increase renal blood flow in humans. Theoretically, this could lead to an increase in glomerular filtration rate and improved renal sodium handling. The present study was designed to test whether patients receiving long‐term nadolol therapy exhibited changes in whole‐body composition that might arise as a consequence. Nine nadolol recipients with angina were followed for up to one year, and serial assessments were made of glomerular filtration rates and whole‐body composition using in vivo neutron activation analysis to assess nitrogen, oxygen, sodium, potassium, chlorine, phosphorous, and calcium. No significant changes in these elements were observed. We conclude that any effect of nadolol on renal blood flow in short‐term studies is not associated with significant changes in body composition measured over a period of one year.